Zobrazeno 1 - 10
of 29
pro vyhledávání: '"BRCA2 germline mutation"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
The v-raf murine sarcoma viral oncogenic homolog B1 (BRAF) V600E is a rare mutation that functions as an oncogenic driver in patients with non-small cell lung cancer (NSCLC) leading to the overactivation of the RAS-RAF-MEK-ERK (MAPK) pathway and the
Externí odkaz:
https://doaj.org/article/376ef64b9e084c62ac2c0666f573f4c5
Autor:
Emiroglu S, Özkurt E, Cabıoglu N, Igci A, Saip P, Yazici H, Ozmen T, Ozmen V, Muslumanoglu M, Tukenmez M
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 15, Pp 163-173 (2023)
Selman Emiroglu,1 Enver Özkurt,2 Neslihan Cabıoglu,1 Abdullah Igci,3 Pinar Saip,4 Hulya Yazici,4 Tolga Ozmen,5 Vahit Ozmen,1 Mahmut Muslumanoglu,1 Mustafa Tukenmez1 1Breast Surgery Unit, Department of General Surgery, Istanbul Faculty of Medi
Externí odkaz:
https://doaj.org/article/1d77e5c8a43146e79bc1eccfc77455b6
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Poly ADP-ribose polymerase inhibitors (PARPis) are widely used for patients with BRCA1/2 mutations. However, until now, there is no available evidence reported for the efficiency of PARPis in cutaneous squamous cell carcinoma (cSCC).Case
Externí odkaz:
https://doaj.org/article/aeef18e254174d27b5935db1f612d1ac
Publikováno v:
European Journal of Case Reports in Internal Medicine (2022)
Prostate cancer is the second most frequent malignancy in men worldwide. Despite the improvement in survival achieved by increasingly early diagnosis and advances in treatment, it is still associated with high mortality. Because of its molecular hete
Externí odkaz:
https://doaj.org/article/b7d42eb8fd5b4ea79a1637ebf402d731
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
BMC Medical Genetics, Vol 19, Iss 1, Pp 1-6 (2018)
Abstract Background Prostate cancer is a heterogeneous disease, meaning patients would benefit from different treatment strategies based on their molecular stratification. In recent years, several genomic studies have identified prostate cancers with
Externí odkaz:
https://doaj.org/article/db52d7f44f5b4a3f9cbea20398dd95e7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jun Hu, Yihong Zhang, Xiaoyan Gan, Fengjiao Zhao, Poshita kumari Seesaha, Xiaofeng Chen, Yong Zhou, Siqin Liu, Yanhong Gu
Publikováno v:
Medicine
Rationale: Immunotherapy and targeted therapy have attracted widespread attention in current clinical research, which could be considered as a good therapeutic option for treatment of refractory liver cancer. Patient concerns: The patient was a 37-ye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bb7e28791e86dad7074ed8efac156a2
http://europepmc.org/articles/PMC7505406
http://europepmc.org/articles/PMC7505406
Publikováno v:
BMC Medical Genetics, Vol 19, Iss 1, Pp 1-6 (2018)
BMC Medical Genetics
BMC Medical Genetics
Background Prostate cancer is a heterogeneous disease, meaning patients would benefit from different treatment strategies based on their molecular stratification. In recent years, several genomic studies have identified prostate cancers with defects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e62b52aca53aaf556b0f516e0e9ffe0a
http://link.springer.com/article/10.1186/s12881-018-0703-9
http://link.springer.com/article/10.1186/s12881-018-0703-9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.